A Cross Sectional Study Evaluating the Mean Levels of Alpha Fetoprotein in Patients of Hepatocellular Carcinoma and Its Correlates in Pakistan

Clinical Correlation of Alpha-Fetoprotein in Hepatocellular Carcinoma: a Cross-Sectional Study from Southeast Asia

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06629857

Enrollment

Registered

2024-10-08

Start date

2022-10-30

Completion date

2023-03-01

Last updated

2024-10-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Carcinoma, Hepatocellular

Keywords

Hepatocellular carcinoma (HCC), Alpha-fetoprotein (AFP) levels, Liver cancer biomarkers, Tumor size and AFP correlation, Hepatitis B and C in liver cancer, Non-alcoholic steatohepatitis (NASH), AFP as a diagnostic tool, Liver tumor progression markers

Brief summary

This study aims to explore the levels of alpha-fetoprotein (AFP), a protein often elevated in liver cancer, in patients with hepatocellular carcinoma (HCC). The goal is to determine whether AFP levels vary based on the size of the liver tumor or other health conditions like hepatitis B, hepatitis C, and obesity. By analyzing data from 94 patients, the study seeks to identify factors that influence AFP levels, which may help in understanding liver cancer progression and improving diagnosis and treatment approaches.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

27 Years to 80 Years

Healthy volunteers

Inclusion criteria

* Aged between 27 to 80 years. * Diagnosed with hepatocellular carcinoma (HCC) within the last three months. * Diagnosis confirmed by relevant investigations (e.g., imaging, liver biopsy). * Able to provide informed consent.

Exclusion criteria

* Elevated alpha-fetoprotein levels due to tumors other than HCC. * Presence of secondary liver metastases from other primary sites. * Any significant comorbid conditions that could interfere with study assessments. * Pregnancy or breastfeeding.

Design outcomes

Primary

Measure	Time frame
Mean Alpha-Fetoprotein (AFP) Levels in HCC Patients	Baseline measurement at time of diagnosis.

Secondary

Measure	Time frame
Correlation Between AFP Levels and Tumor Size	At baseline (upon diagnosis).

Countries

Pakistan

Outcome results